Lung cancer is the deadliest cancer worldwide, accounting for 1.82 million deaths in 2022. The second most deadly form of cancer is colorectum cancer, followed by liver cancer. However, lung cancer is only the sixth leading cause of death worldwide, with heart disease and stroke accounting for the highest share of deaths. Male vs. female cases Given that lung cancer causes the highest number of cancer deaths worldwide, it may be unsurprising to learn that lung cancer is the most common form of new cancer cases among males. However, among females, breast cancer is by far the most common form of new cancer cases. In fact, breast cancer is the most prevalent cancer worldwide, followed by prostate cancer. Prostate cancer is a very close second to lung cancer among the cancers with the highest rates of new cases among men. Male vs. female deaths Lung cancer is by far the deadliest form of cancer among males but is the second deadliest form of cancer among females. Breast cancer, the most prevalent form of cancer among females worldwide, is also the deadliest form of cancer among females. Although prostate cancer is the second most prevalent cancer among men, it is the fifth deadliest cancer. Lung, liver, stomach, colorectum, and oesophagus cancers all have higher deaths rates among males.

In 2022, there were over 9.7 million cancer deaths worldwide. It is projected that the number of deaths due to cancer worldwide will increase to almost 18.5 million by 2050. The most prevalent type of cancer in 2022 was breast cancer with around 48 prevalent cases per 100,000 population. However, lung cancer is by far the deadliest type of cancer.

Lung Cancer Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. In 2022, around 1.82 million cancer deaths, or 19 percent of all cancer deaths worldwide were attributed to lung cancer. Long-term smoking is known to be a major cause of lung cancer. People who never quit smoking are 24 percent more likely to die before age 65 than people who never smoked in their lives.

Treatment In 2023, it was estimated that there were around 4,492 cancer immunotherapy products in R&D phases, as well as another 3,622 other cancer products in the R&D product pipeline. In the same year, it was projected that there were 965 active drugs for breast cancer, as well as 925 active drugs for non-small cell lung cancer.

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

Multi Cancer Screening Market Outlook

The global multi cancer screening market size was valued at approximately $3.5 billion in 2023 and is expected to surge to around $12 billion by 2032, exhibiting a robust CAGR of 15.2% over the forecast period. This remarkable growth is driven primarily by advancements in diagnostic technologies, rising cancer prevalence, and growing awareness about early detection's benefits in improving survival rates. These factors collectively contribute to the market's dynamic expansion, as stakeholders increasingly recognize the value of comprehensive cancer screening solutions.

One of the primary growth factors for the multi cancer screening market is the technological innovation in diagnostic tools. Next-generation sequencing (NGS), polymerase chain reaction (PCR), and advanced imaging techniques have significantly enhanced the accuracy and efficiency of cancer detection. These technologies allow for the simultaneous screening of multiple cancer types, providing a more comprehensive diagnostic approach. The continuous evolution of these technologies promises to further improve detection rates, reduce false positives, and make screenings more accessible and cost-effective.

Another significant contributor to market growth is the increasing awareness and emphasis on early cancer detection. Early diagnosis is crucial for effective treatment and improved survival rates in cancer patients. Governments, healthcare organizations, and non-profit entities are actively promoting early screening programs, leading to a higher adoption rate among the population. Campaigns and educational initiatives highlighting the importance of regular screenings are instrumental in driving market demand.

Breast Cancer Screening Tests have become an integral part of early detection strategies, significantly impacting survival rates. These tests, including mammograms, ultrasounds, and MRIs, are designed to identify breast cancer at its earliest stages, often before symptoms develop. The integration of advanced imaging technologies and genetic testing has further enhanced the accuracy and reliability of these screenings. As awareness grows, more women are participating in regular breast cancer screenings, leading to earlier interventions and improved outcomes. Healthcare providers are increasingly advocating for personalized screening plans based on individual risk factors, ensuring that each patient receives the most appropriate care.

Additionally, the rising global cancer burden is a critical factor propelling the multi cancer screening market. According to the World Health Organization, cancer is one of the leading causes of death worldwide, with millions of new cases diagnosed each year. This alarming increase in cancer incidence underscores the urgent need for effective screening programs. As a result, healthcare systems and providers are investing heavily in multi cancer screening technologies to address this growing health challenge.

Regionally, North America dominates the multi cancer screening market due to its well-established healthcare infrastructure, high healthcare expenditure, and significant investments in research and development. Europe follows closely, with its strong focus on cancer research and public health initiatives. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by improving healthcare facilities, increasing healthcare awareness, and supportive government initiatives in countries like China and India.

Test Type Analysis

The multi cancer screening market is segmented by test type into blood-based, urine-based, tissue-based, and others. The blood-based segment holds the largest market share, primarily due to its non-invasive nature and ease of sample collection. Blood-based tests are preferred for their ability to provide comprehensive insights into multiple cancer types from a single sample. Additionally, these tests are gaining traction due to the advancements in liquid biopsy technologies, which enhance the detection of circulating tumor DNA and other biomarkers.

Urine-based tests are also gaining attention for their non-invasive approach and potential to detect certain cancers at an early stage. These tests are particularly useful for cancers such as bladder and prostate cancer. The convenience and comfort associated with urine sample collection contribute to their increasing adoption. Moreover, ongoing

In a recent report it was shown that the U.S. has the highest prevalence of diagnosed cancer cases among all adults, with around * percent of the adult population having some cancer diagnosis. Cancer is the second leading cause of death from chronic diseases worldwide after cardiovascular diseases.

Global cancer risks

Globally, cancer accounts for about * in every 6 deaths. Many cancer cases are caused by behavioral and dietary risks including tobacco, alcohol and physical inactivity. The prevalence of tobacco smoking is on the decline and is expected to decline further in the future. Smoking has been linked to lung cancer, other upper respiratory cancers and chronic obstructive pulmonary disease (COPD). Among other cancer risk factors, alcohol consumption has been linked to liver and colorectal cancers, as well as other non-communicable diseases. Many European countries have high rates of alcohol consumption.

Global cancer prevalence

Globally, trachea, bronchus and lung cancers are responsible for the most cancer deaths, followed by liver cancer. Lifestyle modification is one of the easiest ways people can reduce their risk of these types of cancer. Among all cancer patients globally, a majority had a history of alcohol consumption. Similarly, in China, EU5 and Russia, over a quarter of all cancer patients had a history of smoking.

According to Cognitive Market Research, the Global Tumor Ablation Market Size was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

• The global Tumor Ablation Market will expand significantly by XX% CAGR between 2024 and 2031. • The radiofrequency tumor ablation segment held the largest share. The dominance can be attributed to its advantages, such as specificity and efficiency in solid tumor ablation procedures in the kidney and liver. • The percutaneous ablation segment accounted for the highest market share during the forecast period. These procedures provide a better security, quicker recovery, and less scarring • Liver cancer dominates the global tumor ablation market, largely due to the high incidence and mortality rates associated with this disease. • Hospitals constitute a significant share of the market due to their comprehensive healthcare services and accessibility to a wide patient demographic. Based on type, demand for Tumor Ablation Devices is increasing. • The North america accounted for the highest market share in the Global Tumor Ablation Market. CURRENT SCENARIO OF THE TUMOR ABLATION MARKET

Driving Factors of Tumor Ablation Market

Tumor Ablation Market Growth is Driven by an Increase in Cancer Prevalence 

Cancer is a globally prevalent disease and a leading cause of death worldwide. For example, the Cancer Australia Statistics for 2022 reported 162,163 new cancer cases diagnosed in Australia, emphasizing the substantial burden it poses. (Source:https://www.canceraustralia.gov.au/impacted-cancer/what-cancer/cancer-australia-statistics)

Similarly, McMillan Cancer Support's October 2022 update revealed that 3 million people were living with cancer in the UK, with projections indicating a steady increase in this number over the coming years. (Source:https://www.macmillan.org.uk/about-us/what-we-do/research/cancer-statistics-fact-sheet)

The market for Tumor ablation is expected to increase as a result of the increasing need for operations and efficient ablation techniques brought about by the rising incidence of cancer. The incidence of cancer has increased due to a sharp rise in the world's senior population as well as harmful modern lifestyles in all age categories. The market for Tumor ablation is becoming more lucrative due to rising costs associated with cancer treatment.

According to data publicly available by WHO, the disease accounts for nearly one in six deaths. WHO further mentions that cancer-causing infections such as hepatitis made up nearly one-third of cancer cases in the global South.

In the U.S., National Cancer Institute forecasted that national estimates of cancer care costs are expected to rise to as high as US$ 173 Bn in 2020. (Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107566/#:~:text=Contribution,increase%20of%2039%25%20from%202010.)

The need for ablation technologies to treat kidney, soft tissue, liver, and bone malignancies is predicted to rise in tandem with the rising incidence of lung, prostate, colon, and breast cancer. Focus on cancer treatment is increasing market income for Tumor ablation.

For instance, in September 2023, the Government of Canada reported that about 28,600 Canadian women were diagnosed with breast cancer in 2022,i.e., 25% of all new cancer cases in women in 2022. (Source:https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/breast-cancer.html)

As a result, the rising global prevalence of cancer is expected to provide considerable growth prospects for market players over the forecast period.

Increasing patients and surgeons’ inclination towards minimally invasive procedures will drive the growth of the market

Smaller incisions or needle insertions are the hallmark of minimally invasive procedures, which have a number of benefits over open surgery. Minimal tissue injury, less blood loss, and a decreased chance of complications are the outcomes of these operations. Minimally invasive surgery patients usually recover more quickly from their procedures and spend less time in the hospital afterward, which improves their quality of life overall and enables them t...

According to Cognitive Market Research, the global Cancer Cachexia market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of XX from 2024 to 2031.

• The global Cancer Cachexia market will expand significantly by XX% CAGR between 2024 and 2031. • North America held a market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Asia Pacific held the major market of more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Latin America's market will have more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • According to Cognitive Market Research, Progestogens is the dominant therapeutic segment for the cancer cachexia market. • According to Cognitive Market Research, Appetite Stimulators is the dominant mechanism action segment for the cancer cachexia market.

Key Dynamics of

Cancer Cachexia Market

Key Drivers of

Cancer Cachexia Market

Rising Global Cancer Incidence: The escalating number of cancer cases globally is directly linked to an increased occurrence of cachexia. As advancements in cancer treatment extend survival rates, the management of cachexia emerges as a vital aspect of palliative care.

Growing Awareness Among Healthcare Providers: Healthcare professionals are progressively acknowledging cachexia as a unique and manageable condition. This transformation is resulting in improved diagnosis, earlier interventions, and a heightened demand for specialized therapies.

Development of Novel Therapeutics: Pharmaceutical firms are channeling resources into groundbreaking treatments that tackle both weight loss and muscle atrophy. The development pipeline features anabolic agents, appetite enhancers, and anti-inflammatory medications, enhancing market opportunities.

Key Restraints for

Cancer Cachexia Market

Limited Approved Treatment Options: In spite of the considerable impact, there are only a handful of FDA-sanctioned medications specifically for cancer cachexia. This scarcity restricts physicians' capacity to deliver consistent and effective treatment across diverse patient groups.

Complex Pathophysiology and Diagnosis: Cancer cachexia encompasses a range of complex mechanisms, complicating its definition, diagnosis, and management. The absence of a unified agreement on clinical criteria frequently postpones appropriate treatment and restricts the adoption of therapeutic options.

Regulatory and Clinical Trial Challenges: Establishing clear endpoints in clinical trials poses difficulties due to the intricate nature of the disease. Regulatory ambiguities and sluggish trial advancements impede the prompt development and approval of new treatment options.

Key Trends in

Cancer Cachexia Market

Enhanced Emphasis on Multimodal Therapy: Healthcare practitioners are increasingly utilizing a blend of pharmacological, nutritional, and physical therapy methods. This comprehensive treatment strategy demonstrates potential in alleviating symptoms more efficiently than single-agent therapy.

Collaborations and Growth in Research Funding: The surge in both public and private investment for cachexia-related research is expediting the process of drug development. Collaborative efforts between biotechnology companies and academic institutions are additionally propelling innovation within this sector.

Patient-Focused Treatment Strategies: Customized care plans designed according to the type and stage of cancer, as well as the overall health of the patient, are becoming more prevalent. The focus is transitioning towards enhancing the quality of life, rather than solely concentrating on physical metrics such as body weight.

Impact of COVID-19 on the Can...

Description: Breast cancer is the most common cancer amongst women in the world. It accounts for 25% of all cancer cases, and affected over 2.1 Million people in 2015 alone. It starts when cells in the breast begin to grow out of control. These cells usually form tumors that can be seen via X-ray or felt as lumps in the breast area. The key challenges against it’s detection is how to classify tumors into malignant (cancerous) or benign(non cancerous). We ask you to complete the analysis of classifying these tumors using machine learning (with SVMs) and the Breast Cancer Wisconsin (Diagnostic) Dataset. Acknowledgements: This dataset has been referred from Kaggle. Objective: Understand the Dataset & cleanup (if required). Build classification models to predict whether the cancer type is Malignant or Benign. Also fine-tune the hyperparameters & compare the evaluation metrics of various classification algorithms.

According to cognitive market research-"Global Oncology Nutrition market size 2023 was XX Million. Oncology Nutrition Industry compound annual growth rate (CAGR) will be XX% from 2024 till 2031."

  The lung cancer segment contributes the most to the market and is predicted to develop at a CAGR of xx% over the forecast period.
  Oral nutrition supplements (ons) are the application category's dominant subsegment.
  Hospitals are the dominant sub-segment in the end-user category. Hospitals play a crucial role in cancer care and treatment, with specialised oncology departments.
  The North American area is the largest contributor to the market and is estimated to grow at a CAGR of xx% during the forecast period due to the rising prevalence of cancer in the American region.
  Asia-Pacific is likely to experience the fastest growth in the oncology nutrition market during the forecast period, owing to rising nutrition awareness initiatives for cancer patients.

Current scenario of the oncology nutrition market

Key drivers of the Oncology Nutrition market

The increasing prevalence of cancer is driving market expansion.

The World Health Organisation (WHO) ranks cancer as the world's second largest cause of death. According to WHO figures, around 25% of cancer patients die as a result of malnutrition caused by sickness or anticancer medication. In 2020, there were an anticipated 18.1 million cancer cases worldwide. There were 9.3 million male and 8.8 million female cases. In 2020, breast and lung cancers accounted for 12.5% and 12.2% of all new cases diagnosed globally, respectively. In 2020, there were around 1.9 million new cases of colorectal cancer, accounting for 10.7% of all new cases. Lung cancer was the most common cancer in men globally in 2020, accounting for 15.4% of all new cases. Lung, prostate, and colorectal cancer accounted for 41.9% of all cancers (excluding non-melanoma skin cancer). Stomach and liver cancers each accounted for more than 5%. In 2020, breast cancer accounted for 25.8% of all new cancer cases diagnosed in women globally. Breast, colorectal, and lung cancers made for 44.5% of all cancer cases (excluding non-melanoma skin cancer). Cervical cancer was the fourth most common cancer among women in 2020, accounting for 6.9% of all newly diagnosed cases. https://www.who.int/news-room/fact-sheets/detail/cancer

Increasingly Ageing Population to Drive Market Expansion

Over 1.5 billion individuals will be elderly in the world in 2050, having doubled in the previous three decades. Between 2019 and 2050, the number of elderly people is expected to rise throughout all regions. However, Eastern and Southeast Asia will see the biggest increase.. The World Health Organisation (WHO) projects that by 2050, the proportion of elderly people worldwide will almost double, from 12% to 22%. The market has enormous potential and is very profitable. Furthermore, the growing older population is predicted to drive the industry's growth in the near future because they are more likely to develop cancer. According to WHO figures, the global population aged 60 and above is expected to exceed 2 billion by 2050. Individuals 65 and older account for almost 60% of all malignancies. Furthermore, this stage accounts for roughly 70% of all cancer-related deaths. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By%202050%2C%20the%20world's%20population,2050%20to%20reach%20426%20million.

Constraints for the global Oncology Nutrition market

High Cost and complications of Oncology Nutrition Products

The high cost of oncology nutrition products is a major barrier to growth in the global industry. Cancer patients may require specialised goods with precise nutrient formulations to suit their dietary needs. Specialised goods are more expensive than ordinary nutritional supplements due to increased costs for research, manufacturing, and quality control. Personalised nutrition planning and counselling services increase the expense of oncology nutrition. The high cost of these products may limit their accessibility and affordability, especially for lower-income individuals or patients. Tube feeding difficulties are projected to slow the oncology nutrition market's development pace. Constipation, dehydration,...

With the increasing number of people suffering from cancer, this illness has become a major health problem worldwide. Exploring the biological functions and signaling pathways of carcinogenesis is essential for cancer detection and research. In this study, a mutation dataset for eleven cancer types was first obtained from a web-based resource called cBioPortal for Cancer Genomics, followed by extracting 21,049 features from three aspects: relationship to GO and KEGG (enrichment features), mutated genes learned by word2vec (text features), and protein-protein interaction network analyzed by node2vec (network features). Irrelevant features were then excluded using the Boruta feature filtering method, and the retained relevant features were ranked by four feature selection methods (least absolute shrinkage and selection operator, minimum redundancy maximum relevance, Monte Carlo feature selection and light gradient boosting machine) to generate four feature-ranked lists. Incremental feature selection was used to determine the optimal number of features based on these feature lists to build the optimal classifiers and derive interpretable classification rules. The results of four feature-ranking methods were integrated to identify key functional pathways, such as olfactory transduction (hsa04740) and colorectal cancer (hsa05210), and the roles of these functional pathways in cancers were discussed in reference to literature. Overall, this machine learning-based study revealed the altered biological functions of cancers and provided a reference for the mechanisms of different cancers.

Electrolarynx Market size was valued at USD 408.5 Million 2023 and is projected to reach USD 702.1 Million by 2030, growing at a CAGR of 4.5% during the forecasted period 2024 to 2030

Global Electrolarynx Market Drivers

The growth and development of the Electrolarynx Market drivers. These factors have a big impact on how Electrolarynx are demanded and adopted in different sectors. Several of the major market forces are as follows:

Rising Laryngeal Cancer Incidence: People who have had laryngectomy surgery for laryngeal cancer frequently utilise the Electrolarynx as an assistive device. The need for Electrolarynx devices as a communication aid for those affected by laryngeal cancer is being driven by the disease's rising occurrence.

Technological Developments in Electrolarynx Devices: The increasing popularity of Electrolarynx devices can be attributed to the continuous breakthroughs in technology, which offer enhanced voice quality, longer battery life, and more portability. Innovations broaden the market and improve the customer experience.

Increasing Accessibility and Awareness: Higher adoption rates are a result of patients, carers, and healthcare professionals being more aware of the range of voice restoration alternatives available, including Electrolarynx devices. One factor contributing to these gadgets' growing market share is improved accessibility.

Growing Senior Population: Ageing adults are more likely to have diseases like cancer that can necessitate laryngectomy. Individuals are more likely to require voice restoration treatments, such as Electrolarynx devices, as the world's population ages.

The prevalence of chronic respiratory disorders is a significant concern: Patients with chronic obstructive pulmonary disease (COPD), for example, may need laryngectomy treatments. The need for voice restoration tools like the Electrolarynx is fueled in part by the incidence of these respiratory disorders.

According to Cognitive Market Research, the global Renal Cell Carcinoma Drugs market size was USD XX million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
The Targeted Therapy Type held the highest Renal Cell Carcinoma Drugs market revenue share in 2024.

Market Dynamics of Renal Cell Carcinoma Drugs Market

Key Drivers for Renal Cell Carcinoma Drugs Market

Increased Incidence of Kidney Diseases to Increase the Demand Globally

The global rise in chronic kidney disease (CKD) is significantly driving the growth of the kidney cancer drugs market. According to the National Kidney Foundation, approximately 10% of the population is affected by CKD. Renal cell carcinoma (RCC) comprises over 90% of all kidney cancers, while renal pelvis cancer accounts for less than 10% of microscopically confirmed kidney carcinomas. Clear cell renal cell carcinoma is the most common subtype of RCC, affecting around 70% of RCC patients. This increasing incidence necessitates a greater demand for kidney cancer drugs.

Increase in the elderly population to Propel Market Growth

The global increase in the elderly population is a significant driver, as renal cell carcinoma (RCC) is more common in older adults. Between 2015 and 2050, the proportion of the world's population over 60 years will nearly double, rising from 12% to 22%. By 2030, one in six people worldwide will be aged 60 years or older. The number of people aged 60 years and above is projected to grow from 1 billion in 2020 to 1.4 billion by 2030. By 2050, this figure will double to 2.1 billion. Additionally, the population of individuals aged 80 years or older is expected to triple from 2020 to 2050, reaching 426 million. This rise in the geriatric demographic is anticipated to result in a higher incidence of RCC, thereby increasing the demand for treatment options.

Restraint Factor for the Renal Cell Carcinoma Drugs Market

High Cost of Treatment, and Side Effects of Kidney Cancer Drugs to Limit the Sales

RCC treatments, particularly targeted therapies and immunotherapies, are often very expensive. High costs can limit accessibility for many patients, especially in low- and middle-income countries with constrained healthcare budgets. The significant out-of-pocket expenses associated with RCC treatments can be a financial burden for patients, even in countries with robust healthcare systems, leading to reduced treatment adherence and demand. Additionally, major side effects related to these kidney cancer drugs, such as loss of appetite, fever, and rashes, could hinder the growth of the kidney cancer drugs market during the forecast period.

Impact of Covid-19 on the Renal Cell Carcinoma Drugs Market

The pandemic significantly disrupted healthcare services, causing delays in the diagnosis and treatment of RCC. Many patients postponed routine check-ups and screenings, resulting in late-stage diagnoses. Restrictions on non-emergency medical procedures and the fear of contracting the virus led to a decline in hospital visits, impacting the initiation and continuation of RCC treatment. Additionally, numerous clinical trials for RCC drugs were temporarily suspended or delayed due to COVID-19, affecting the development pipeline and slowing the approval of promising new treatments. Introduction of the Renal Cell Carcinoma Drugs Market

The Renal Cell Carcinoma (RCC) Drugs Market is a rapidly evolving segment within the global oncology market, fueled by advancements in medical ...

Bladder cancer (BC) is a significant global public health concern, affecting a large number of people worldwide. Therefore, discovering effective strategies for its prevention and treatment is crucial to minimise its impact. Apigenin is a flavonoid found in fruits and vegetables. Studies have shown its effectiveness in treating various types of cancer. This review summarises the mechanisms of action and therapeutic effects of apigenin in treating BC. According to our findings, apigenin affects various signalling pathways and numerous protein families, including p53, caspase, PARP, cytochrome c, Bcl-2, PI3K/Akt, ERK1/2, JNK, AP-1, NF-κB, MAPK, MEKK1, and TRAIL, leading to cell death and inhibition of proliferation and migration in cancer cells. Thus, apigenin may represent a promising therapeutic approach for BC. However, the encouraging preclinical data should be evaluated in clinical settings through further studies, with appropriate methods and enhanced drug delivery systems.

According to Cognitive Market Research, the global Metastatic Bone Disease market size will be USD 18624.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 8.90% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 6891.18 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 5401.19 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 4469.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 707.74 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 744.99 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 409.75 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2033.
Medication category is the fastest growing segment of the Metastatic Bone Disease industry

Market Dynamics of Metastatic Bone Disease Market

Key Drivers for Metastatic Bone Disease Market

Rising Prevalence of Cancer, Especially Breast, Prostate, and Lung Cancer to Boost Market Growth

The rising incidence of primary cancers—particularly breast, prostate, and lung cancers, which have a high propensity to metastasize to bones—is a key driver of the global metastatic bone disease market. According to data from IARC’s Global Cancer Observatory, 2022 saw an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. Approximately 53.5 million individuals were living within five years of a cancer diagnosis, highlighting the growing survivor population at risk for metastatic complications. Globally, around 1 in 5 people will develop cancer in their lifetime, with approximately 1 in 9 men and 1 in 12 women dying from the disease. Ten major cancer types accounted for nearly two-thirds of new cases and deaths across 185 countries. Lung cancer was the most diagnosed cancer globally in 2022, with 2.5 million new cases (12.4% of all cases), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million, 9.6%), prostate cancer (1.5 million, 7.3%), and stomach cancer (970,000, 4.9%). Lung cancer also led in mortality, with 1.8 million deaths (18.7%), followed by colorectal (900,000), liver (760,000), breast (670,000), and stomach cancer (660,000) deaths. As advancements in diagnostic technologies and increased life expectancy continue, the global cancer burden is rising. Because bone is a frequent site of metastasis in late-stage cancers, longer survival rates and improved awareness are leading to more patients developing bone complications. This, in turn, is driving growing demand for effective therapies, diagnostics, and long-term monitoring solutions in the metastatic bone disease market.

https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services/.//./

Growing Geriatric Population Susceptible to Bone Complications to Boost Market Growth

The global elderly population is expanding rapidly, especially in developed regions such as North America, Europe, and parts of Asia-Pacific. By 2030, it is projected that 1 in 6 people worldwide will be aged 60 years or older. The number of people in this age group is expected to grow from 1 billion in 2020 to 1.4 billion by 2030, and further double to 2.1 billion by 2050. Additionally, the population aged 80 years and above is anticipated to triple, reaching approximately 426 million by 2050. Between 2015 and 2050, the share of the global population over 60 is projected to rise from 12% to 22%. This demographic shift is a critical driver for the metastatic bone disease market, as older individuals are inherently more susceptible to cancer and bone-related conditions due to physiological aging and reduced bone density. Since metastatic bone disease primarily affects elderly cancer patients, the growing aging p...

Snapshot img { margin: 10px !important; } Get an impression below about how you can gain compelling insights from Technavio’s market research report? Check out the latest facts about the brain cancer imaging industry

The global brain cancer imaging market is expected to grow at a CAGR of over 5% during the forecast period

Brain cancer imaging industry growth is expected to accelerate over the next five years, driven by growing incidences of brain cancer across the globe. The Americas will drive around 45% of the growth of the brain cancer diagnosis industry, while EMEA and APAC are also predicted to contribute sizably to the incremental growth in the forecast period. The number of people diagnosed with brain cancer has increased significantly in the recent past and cancer is considered as one of the most leading causes of death worldwide. Brain cancer is one of the most important types of cancer and its rising prevalence is expected to drive the demand for treatment with radiotherapy for brain cancer. Technavio’s brain cancer imaging industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Brain cancer MRI systems are the leading brain cancer imaging product segment

The dominating product segment in the brain cancer imaging market was MRI systems in 2017 with a market share of 45% in 2017. Brain cancer MRI systems was followed by product segments of CT systems, PET scanners, and others segment. Also, the brain cancer MRI systems segment will continue to dominate the market during the forecast period while PET scanners will witness a faster growth than CT systems and others segment in the next five years. The global brain cancer imaging industry is experiencing significant advancements in technology such as 3D medical imaging equipment, which is likely to boost the growth of the market in the coming few years.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services. Start your 14-day FREE trial

Canon, GE Healthcare, and Hitachi are among the leading brain cancer imaging vendors

Most of the leading vendors in the brain cancer imaging market are moving hybrid imaging technologies and ensuring the availability of portable and easy-to-use brain cancer imaging devices. The global brain cancer imaging market is forecasted to remain reasonably concentrated with the presence of a few established brain cancer imaging vendors who offer equipment for brain cancer imaging and radiotherapy for brain cancer. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

Canon
GE Healthcare
Hitachi
Koninklijke Philips
Samsung Electronics
Siemens Healthineers

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch

According to cognitive market research, the global antiemetics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

The drugs or medications which help to prevent and treat conditions such as nausea, and vomiting are referred to as antiemetic drugs.
North America dominated the market with a share of xx% in 2024. The existence of major companies like Pfizer and GSK plc is probably going to increase the region's revenue share.
The Asia Pacific market is expected to grow at a significant CAGR from 2024 to 2031. The region's market is anticipated to be supported by rising cancer and gastroenteritis incidence rates as well as the expanding availability of antiemetics.
The Middle East and Africa market is expanding as a result of the rapidly ageing population and an increase in cancer patients.
Leading players in the market are constantly involved in a range of strategic activities designed to maintain and strengthen their position within the industry.

Market Dynamics of the Antiemetics Market

Key Drivers of the Antiemetics Market

The rising prevalence of cancer will propel the market growth

The industry's growth will be supported by the rising number of cancer sufferers. Because cardiovascular ailments are on the rise, the industry is growing. In the twenty-first century, cancer is a significant social, public health, and economic issue. It accounts for about one in six fatalities (16.8%) and one in four deaths (22.8%) from noncommunicable diseases (NCDs) globally. Approximately 9–10 million people die from cancer each year. Lung and breast cancer are the two most common types, and their occurrence has increased significantly. Of the 2.3 million instances of breast cancer that were identified worldwide in 2021, 680,000 people died from the disease. Similarly, the prevalence of lung cancer is rising as a result of the increased smoking trend. According to research, smoking is the primary cause of 82% of occurrences of lung cancer. Antiemetics, commonly referred to as antinausea medications, are effective in preventing or minimizing nausea and vomiting, which are common adverse effects of cancer therapies. (Source:https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834 ) (Source:https://www.who.int/news-room/fact-sheets/detail/breast-cancer )

Increasing the number of drug approvals and ongoing research activities significantly drives the market. 

Antiemetic medication research, development, and approval processes include a large number of industry actors. By increasing financing, several government agencies seek to improve the healthcare system and further modify the dynamics of the market. The yearly New Drug Therapy Approvals Report provides information on the 55 innovative medications that CDER authorised in 2023. A unique drug's active component or ingredients have never received FDA approval before. Over the course of the forecast period, the launch and approval of such goods are expected to play a major role in driving market expansion. Five biosimilars were authorised by CDER in 2023, three of which were biosimilars for reference products for which there was no prior biosimilar. For 14 reference products, CDER has authorised 45 biosimilars thus far. (Source:https://www.fda.gov/news-events/fda-voices/fda-approves-many-new-drugs-2023-will-benefit-patients-and-consumers ) • For instance, in March 2023, Taiho Pharmaceutical Co., Ltd. received authorization to market and manufacture Arokaris, a selective NK1 receptor antagonist antiemetic drug designed for gastrointestinal symptoms associated with cancer chemotherapy. (Source:https://www.taiho.co.jp/en/release/2022/20220525.html )

Restraints of the Antiemetics Market

High entry barriers for new players may hamper the market

One of the main issues preventing the industry from expanding is the high entry barriers for new companies. It is extremely difficult for SMEs to develop innovative items that may succeed in the market because of the existence of larger market participants. Additionally, buyers' switching costs and the public businesses' credibility play a major impact in the market condition. It is also very difficult for younger businesses to get into the market since these larger corporations have extensive distribut...

Snapshot img { margin: 10px !important; } Below are some of the key findings from the cell separation technologies market research report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global cell separation technologies industry overview

Increase in chronic diseases is one of the key factors contributing to the growth of the market. Experts have identified that chronic diseases are one of the major causes of disability and death across the globe. CVDs, cancer, chronic obstructive pulmonary disease (COPD), and type 2 diabetes are the four major chronic diseases. They occur due to high blood pressure, high blood cholesterol, and obesity caused by unhealthy diet and physical inactivity among others. By 2020, it is expected that chronic diseases will cause 72.94% of all deaths globally and 59.96% of the global burden of diseases. Chronic diseases such as heart disease, asthma, cancer, and diabetes are not curable. However, these diseases can be prevented by implementing an improved diet, exercise, early detection, and thorough treatment therapies such as cell therapy.

The growing prevalence of cancer is one of the key cell separation technologies market trends that will gain traction in the coming years. Cancer is among the top five causes of death among people of all ages globally. Most cancer types are curable, especially when diagnosed in the early stages. A full array of interventions is required for many common cancer types. Cell-based assays, which use cell separation techniques are currently one of the advanced molecular biology techniques that are used in research to diagnose many forms of cancer. The cytogenetic analysis of tumor material has improved over the past 15 to 20 years by the application of cell separation techniques, which offer advantages such as the specific detection of cancer cells by their differential labeling and reproducible emission spectra. Cell separation can be used to separate genetic and structural aberrated cells. Further, the increase in awareness regarding cancer is making people and governments take preventive steps to reduce the economic burden caused by cancer on healthcare expenditure. This is expected to increase the adoption of cell-based assays, which require cell separation techniques, thereby driving the market to grow at a CAGR of over 17% during the forecast period.

Top cell separation technologies companies covered in this market research report

The cell separation technologies market is fairly fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this cell separation technologies industry analysis report will aid clients to identify new growth opportunities and design new growth strategies.

The report offers a complete analysis of various companies including:

BD
Bio-Rad Laboratories
Danaher
GENERAL ELECTRIC
Merck Group
Thermo Fisher Scientific

Cell separation technologies market segmentation based on geographic regions

Americas
APAC
EMEA

With a complete study of the growth opportunities for the companies, the Americas will account for the highest growth of this market throughout the forecast period. Several biotechnology and pharmaceutical companies have come up in the Americas which are primarily driving growth within the cell separation technologies market size.

Cell separation technologies market segmentation based on end users

Research laboratories and institutes
Biotechnology and pharmaceutical industries

The research laboratories and institutes segment will account for the highest growth in the market. Cell separation technique is an essential step in cell-based assays. This technique is extensively used in research laboratories and institutes and it increases the cell separation technologies market value. Additionally, the report also provides an accurate prediction of the contribution of the various end-user segments to the growth of the cell separation technologies market size.

Key highlights of the global cell separation technologies market for the forecast years 2018-2022:

CAGR of the market during the forecast period 2018-2022
Detailed information on factors that will accelerate the growth of the cell separation technologies market during the next five years
Precise estimation of the global cell separation technologies market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the cell separation technologies industry across the Americas, APAC, and EMEA
A thorough analysis of the market’s competitive landscape and detailed information on several vendors
Comprehensive details on the factors that will challenge the growth of cell separation technologies companies

We can help! Our analysts can customize this market research re

According to Cognitive Market Research, the global Cancer Therapeutics and Biotherapeutics market size was USD 175181.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 8.80% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 70072.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 52554.45 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 40291.75 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.8% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 8759.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 3503.63 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
The lung cancer category is the fastest growing segment of the Cancer Therapeutics and Biotherapeutics industry

Market Dynamics of Cancer Therapeutics and Biotherapeutics Market

Key Drivers for Cancer Therapeutics and Biotherapeutics Market

The Growing Number of Cancer Cases Worldwide to Boost Market Growth

The global increase in cancer incidence and prevalence is one of the main factors propelling the market for cancer therapies and biotherapeutics. The need for novel and efficient therapies keeps growing as more people are being diagnosed with different illnesses, such as colorectal, lung, and breast cancers. Numerous new treatments, such as targeted therapies, immunotherapies, and sophisticated biologics, have been developed as a result of increased research efforts brought on by this expanding patient population. Globally, cancer rates are also rising due to ageing populations, environmental concerns, and changes in lifestyle, which increase the demand for affordable and efficient therapies. In order to address this pressing health issue, the market for therapeutic breakthroughs and biotherapeutics will keep growing as cancer rates rise.

Advancements in Immunotherapy and Biologics to Drive Market Growth

The market for cancer therapies and biotherapeutics is expanding due in large part to developments in immunotherapy and biologics. Compared to conventional therapies, immunotherapy, which includes immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, offers substantial advantages by using the immune system to target and kill cancer cells. By targeting cancer cells directly, biologics like modified T cells and monoclonal antibodies can improve patient outcomes by minimizing collateral damage to healthy cells. Increased investment and research in this field have resulted from these advances' impressive efficacy across a range of cancer types. It is anticipated that the market for cancer treatments will continue to expand as these treatments become more widely available and efficient.

Restraint Factor for the Cancer Therapeutics and Biotherapeutics Market

Risk of Adverse Side Effects Will Limit Market Growth

The market for cancer treatments and biotherapeutics is significantly constrained by the possibility of unfavourable side effects linked to numerous treatments. Even though immunotherapy and targeted therapies are frequently more accurate, they can nevertheless have major adverse effects, such as organ damage, severe allergic reactions, and immune-related problems. These adverse effects may affect the general uptake of these medicines by discouraging patient compliance, restricting therapeutic dosage, and raising management expenses. Additionally, regulatory bodies may be reluctant to authorize treatments that raise serious safety issues, which would impede market expansion. In order to boost patient acceptance and increase the use of modern cancer medicines, these safety concerns must be addressed.

Impact of Covid-19 on the Cancer Therapeutics and Biotherapeutics Market

The COVID-19 pandemic had a major effect on the market for cancer therapies and biotherapeutics by interfering with clinical trials, research, and the accessibility of treatments. Many cancer patients faced delaye...

Early Cancer Detection Market Outlook

The global early cancer detection market size was estimated to be USD 4.3 billion in 2023 and is projected to reach USD 12.9 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.6% during the forecast period. This rapid growth is driven by advancements in medical technology, increasing awareness about the benefits of early detection, and rising prevalence of cancer worldwide.

One of the key growth factors for this market is the significant advancements in medical imaging technologies and biomarker research. The continuous innovation in these fields has led to the development of more precise and less invasive diagnostic tests, enhancing the ability to detect cancer at its earliest stages. Moreover, these advancements help reduce the overall costs associated with cancer treatment by enabling timely interventions, which are generally less expensive and have higher success rates compared to treatments for advanced-stage cancers.

Another critical growth driver is the growing awareness and initiatives by governments and healthcare organizations to promote early cancer screening programs. Many countries are establishing national screening programs, covering various types of cancer such as breast, colorectal, and cervical cancer. These programs are supported by campaigns that educate the public on the importance of early detection, which in turn fuels the demand for diagnostic tests. Additionally, legislative measures and reimbursement policies are increasingly becoming favorable, encouraging more individuals to participate in routine screenings.

The rise in the elderly population globally also significantly contributes to market growth. As age is a major risk factor for cancer, the increasing geriatric population implies a higher demand for early detection tests. With more people living longer, there is an escalating need to diagnose and treat cancers early to improve survival rates and quality of life. Thus, demographic shifts are expected to sustain the growth momentum in the early cancer detection market over the forecast period.

From a regional perspective, North America currently dominates the early cancer detection market, driven by high healthcare expenditure, advanced healthcare infrastructure, and a strong focus on research and development. The Asia Pacific region is anticipated to witness the highest growth rate during the forecast period due to increasing healthcare investments, rising awareness about early cancer detection, and improving healthcare infrastructure. Europe also holds a significant share, benefiting from comprehensive cancer screening programs and supportive governmental policies.

Head and Neck Cancer Diagnostics have seen significant advancements in recent years, driven by the need for early detection and improved patient outcomes. These diagnostics often involve a combination of imaging techniques, such as MRI and CT scans, alongside biomarker and genetic tests. The integration of these methods allows for a comprehensive assessment of potential head and neck cancers, facilitating timely intervention. As technology progresses, the accuracy and efficiency of these diagnostic tools continue to improve, offering hope for better survival rates and quality of life for patients. The ongoing research in this area is crucial, as head and neck cancers can be particularly aggressive, making early detection vital.

Test Type Analysis

The early cancer detection market is segmented into several test types, including Imaging, Biomarker Tests, Liquid Biopsy, Genetic Tests, and Others. Imaging tests, such as mammograms, CT scans, and MRIs, have long been a staple in cancer detection. These modalities offer non-invasive visualization of internal structures, allowing for the identification of tumors at an early stage. Continued advancements in imaging technology, such as higher resolution and 3D imaging, are enhancing diagnostic accuracy and expanding the applications of these tests in oncology.

Biomarker tests represent another significant segment within the early cancer detection market. These tests detect specific proteins, genes, or other biomarkers that are indicative of cancer. The rising focus on personalized medicine and targeted therapies is driving the demand for biomarker tests, as they can provide valuable information about an individual's cancer type and potential treatment responses. Technological advancements in assay

Rapid Tumor Marker Tests Market Outlook

The global market size for rapid tumor marker tests was valued at approximately USD 4.2 billion in 2023 and is expected to reach USD 7.8 billion by 2032, growing at a CAGR of 7.1% during the forecast period. The escalating incidence of cancer cases worldwide coupled with advancements in healthcare technology are significant growth factors driving this market. Rapid tumor marker tests are essential for the early detection, diagnosis, and treatment of various cancers, which significantly enhances patient outcomes and survival rates.

One of the primary growth factors propelling the market is the increasing prevalence of cancer globally. As per the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. This alarming rise in cancer cases necessitates the demand for efficient diagnostic tests like rapid tumor marker tests. These tests enable healthcare professionals to detect cancer at an early stage, which is crucial for effective treatment and management, thereby driving the market growth.

Another crucial factor contributing to market expansion is the continuous advancements in biotechnology and diagnostic technologies. Innovations in biomarker discovery and molecular diagnostics have led to the development of more precise, accurate, and rapid tumor marker tests. Companies are investing significantly in research and development to introduce advanced tests that can detect a wide range of cancers with high specificity and sensitivity. These technological advancements are expected to fuel market growth during the forecast period.

Furthermore, the growing awareness among the population regarding the importance of early cancer detection is driving the demand for rapid tumor marker tests. Public health campaigns and initiatives by governments and non-profit organizations are educating people about the benefits of early diagnosis and regular screenings. This increased awareness is encouraging more individuals to opt for tumor marker tests, thereby boosting market growth. Additionally, favorable reimbursement policies for cancer diagnostics in several countries are also contributing to the market expansion.

From a regional perspective, North America holds a significant share in the rapid tumor marker tests market due to the high prevalence of cancer, advanced healthcare infrastructure, and the presence of key market players in the region. Europe follows closely due to similar factors, along with supportive government initiatives for cancer research and diagnostics. The Asia Pacific region is anticipated to witness substantial growth during the forecast period, driven by rising healthcare expenditure, increasing awareness about cancer diagnostics, and a growing number of diagnostic laboratories.

Product Type Analysis

The rapid tumor marker tests market is segmented based on product type into protein markers, genetic markers, and others. Protein markers are among the most widely used biomarkers for cancer detection. They offer several advantages such as ease of detection and quantification through various immunoassays. Protein markers, including PSA (Prostate-Specific Antigen), CA-125 (Cancer Antigen 125), and CEA (Carcinoembryonic Antigen), are critical in diagnosing and monitoring different types of cancers. The high adoption rate of protein markers in clinical settings is driving the growth of this segment.

Genetic markers, on the other hand, are gaining prominence due to their ability to provide detailed information about the molecular changes associated with cancer. These markers include specific gene mutations, amplifications, or methylation patterns that can indicate the presence of cancer. Genetic markers such as BRCA1 and BRCA2 for breast cancer and KRAS for colorectal cancer are employed in both diagnostic and prognostic applications. The growing focus on personalized medicine and targeted therapies is propelling the demand for genetic markers.

Other types of tumor markers, including circulating tumor cells (CTCs) and miRNA (microRNA), represent a smaller but rapidly growing segment of the market. These markers offer the potential for non-invasive or minimally invasive cancer detection. For instance, CTCs can be detected through a simple blood test, which is less invasive compared to traditional biopsy methods. The increasing research and development activities in this area are expected to drive the growth of this segment in the coming years.

Each type of tumor marker has it